IP Library › Patent Application 18610343
Patent Application
App. No. 18/610,343

METHOD OF INITIATING OR ESCALATING DOFETILIDE DOSE AND FORMULATIONS THEREFOR

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/610,343
Abstract

The present invention provides a novel method of initiating or escalating dofetliide dosage with the goal of maximizing patient safety while shortening the time period required for electrocardiogramonitoring from three days to one day.

Claims (15)

1 - 20 . (canceled)

21 . A method of rapidly titrating and chronically administering dofetilide, comprising:

(a) intravenously infusing a dofetilide pharmaceutical composition to deliver 1.8-3.0 μg/kg of dofetilide to a patient in need of chronic oral dofetilide therapy;

(b) measuring the QTc of the patient;

(c) after completion of the intravenous administration, orally administering a first 500 μg dose of dofetilide;

(d) chronically administering 500 μg dofetilide orally, twice daily;

provided that if the patient's QTc has increased by 15% over baseline QTC or if the QTc greater than 500 msec (550 msec seen in patients with ventricular conduction abnormalities), the chronic oral dosages of dofetilide are reduced to 250 μg;

wherein the dofetilide pharmaceutical composition is suitable for intravenous administration and, comprises: 10-1000 μg/mL dofetilide and water and has pH 6-7.

22 . The method according to claim 21 , wherein the dofetilide pharmaceutical composition has a storage stability of 3 months at room temperature.

23 . The method according to claim 21 , wherein the dofetilide pharmaceutical composition has a dofetilide concentration of 10-100 μg/mL.

24 . The method according to claim 23 , wherein the dofetilide pharmaceutical composition has a dofetilide concentration of 50 μg/mL.

25 . The method according to claim 1 , wherein dofetilide is infused intravenously at 2.0-2.8 μg/kg of dofetilide to the patient in need of chronic oral dofetilide therapy.

26 . The method according to claim 1 , wherein dofetilide is infused intravenously at 2.2-2.6 μg/kg of dofetilide to the patient in need of chronic oral dofetilide therapy.

27 . The method according to claim 1 , wherein dofetilide is infused intravenously over a period of 5-30 minutes.

28 . The method according to claim 1 , wherein the patient presents with intermittent atrial fibrillation.